Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ARIES-3: A Phase 3, Long-Term, Open-Label, Multicenter Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension

NCT00380068 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00380068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00380068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ARIES-3: A Phase 3, Long-Term, Open-Label, Multicenter Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2006
Completion date
May 31, 2009
Enrollment
224 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary hypertension